Targeting ErbB receptors in breast cancer;Cancer du sein et ciblage des récepteurs ErbB (HER)

Bulletin du Cancer

Volumn 94, Issue SUPPL. 7, 2007, Pages

  Fumoleau, Pierre ^a   Campone, Mario ^a   Coudert, Bruno ^a   Mayer, Françoise ^a   Favier, Laure ^a   Ferrant, Emanuelle ^a  

^a NONE

Author keywords

Breast cancers; EGFR; ErbB2; HER2; Lapatinib; Trastuzumab

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ABT 869; AG 028262; AGO 13736; ANASTROZOLE; AXITINIB; BMS 536924; BMS 582664; CANERTINIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CHIR 258; CISPLATIN; CP 547 632; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; E 7080; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; GW 86034; KRN 951; LAPATINIB; LETROZOLE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NAVELBINE; OSI 930; PACLITAXEL; PAZOPANIB; PERTUZUMAB; SORAFENIB; SUNITINIB; TELATINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VANTETANIB; XL 820; XL 999; XL7 184;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CYTOTOXICITY; DISEASE COURSE; DRUG MECHANISM; DRUG TARGETING; HUMAN; METASTASIS; MONOTHERAPY; PALLIATIVE THERAPY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 36348955016     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0432     Document Type: Review

References (125)

1. Tronick SR, Aaronson SA. Growth factor and signal transduction. In : Molecular basis of cancer. Mendelsohn, Howley. Israel, Liotta : Eds Saunders, 1995.
2. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003 ; 284 : 99-110.
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001 ; 2 : 127-37.
4. Nahta R, Hortobágyi GN, Esteva FJ. Growth factor receptors in breast cancer : potential for therapeutic intervention. Oncologist 2003 ; 8 : 5-17.
5. Rowinsky EK. Targeting signal transduction. Horiz Cancer Ther 2001 ; 2 : 3-35.
6. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network : receptor heterodimerization in development and cancer. EMBO J 2000 ; 19 : 3159-67.
7. Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997 ; 16 : 1647-55.
8. Moscatello DK, Holgado-Madruga M, Emlet DR, et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998 ; 273 : 200-6.
9. Wikstrand CJ, McLendon RE, Friedman AH, et al. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997 ; 57 : 4130-40.
10. Olapade-Olaopa EO, Moscatello DK, MacKay EH, et al. Evidence for the differential expression of a variant EGF receptor prorein in human prostate cancer. Br J Cancer 2000 ; 82 : 186-94.
11. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 ; 244 : 707-12.
12. Pupa SM, Menard S, Morelli D, et al. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 1993 ; 8 : 2917-23.
13. Christianson TA, Doherty JK, Lin YJ, et al. NH2-terminally truncated HER-2/neu protein : relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998 ; 58 : 5123-9.
14. Segatto O, King CR, Pierce JH, et al. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 1988 ; 8 : 5570-4.
15. Colomer R, Montero S, Lluch A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000 ; 6 : 2356-62.
16. Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997 ; 15 ; 2518-25.
17. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signalling network : receptor heterodimerization in development and cancer. EMBO J 2000 ; 19 : 3159-67.
18. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001 ; 37(suppl 4) : S9-S15.
19. Nahta R, Hortobágyi GN, Esteva FJ. Growth factor receptors in breast cancer : potential for therapeutic intervention. Oncologist 2003 ; 8 : 5-17.
20. Xia W, Mullin RJ, Keith BR, et al. Anti-tumour activity of GW572016 : a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002 ; 21 : 6255-63.
21. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001 ; 1 : 85-94.
22. Klohs WD, Fry DW, Kraker AJ. Inhibitors of tyrosine kinase. Curr Opin Oncol 1997 ; 9 : 562-8.
23. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999 ; 17 : 2639-48.
24. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002 ; 20 : 719-26.
25. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 ; 344 : 783-92.
26. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment : the M77001 study group. J Clin Oncol 2005 ; 23 : 4265-74.
27. Gasparini G, Gion M, Mariani L, et al. Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 2007 ; 101 : 355-65.
28. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2 - overexpressing metastatic breast cancer. J Clin Oncol 2006 ; 24 : 2786-92.
29. Forbes JF, Kennedy J, Pienkowski T, et al. BCIRG 007 : randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer : main time to preogression analysis. J Clin Oncol 2006 ; 24 : 18S ; (abstract 516).
30. Wardley A, Torres A, Pivot X, et al. Trastuzumab plus docetaxel with or without capecitabine in patients with HER-2 positive advanced/metastatic breast cancer. Primary efficacy results from a randomized phase II study (CHAT). Ann Oncol 2006 ; 17(Suppl 9).
31. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001 ; 19 : 2587-95.
32. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002 ; 20 : 1800-8.
33. Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A, et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 2001 ; 12 : 1545-51.
34. Jahanzeb M, Mortimer JE, Yunus F, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2 (+) metastatic breast cancer. Oncologist 2002 ; 7 : 410-7.
35. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer : multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003 ; 21 : 2889-95.
36. Tedesco KL, Thor AD, Johnson DH, et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3 overexpressing and fluorescent in situ hybridization - positive metastatic breast cancer : a multi-institutional phase II Trial. J Clin Oncol 2004 ; 22 : 1071-7.
37. Fountzilas G, Christodoulou C, Tsavdaridis D, et al. Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer : a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest 2004 ; 22 : 655-62.
38. Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer : NCCTG study 983252. Clin Breast Cancer 2005 ; 6 : 425-32.
39. Chan A, Martin M, Untch M, et al. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients : an international phase II trial. Br J Cancer 2006 ; 95 : 788-93.
40. Brufsky A, Fox K, Orlando M, et al. Phase II study of gemcitabine and trastuzumab combination therapy in first line metastatic breast cancer patients with HER2 overexpression. J Clin Oncol 2006 ; 24 : 18S ; (Abstract 10591).
41. Leyland-Jones B, Gelmon K, Ayoub JP, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003 ; 21 : 3965-71.
42. Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in her2-positive advanced breast cancer. J Natl Cancer Inst 2004 ; 96 : 759-69.
43. Montemurro F, Choa G, Faggiuolo R, et al. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 2004 ; 66 : 38-45.
44. Untch M, Eidtmann H, du Bois A, et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer : results of a phase I trial. Eur J Cancer 2004 ; 40 : 988-97.
45. Sato N, Sano M, Tabei T, et al. Combination docetaxel and trastuzumab treatment for patients with her-2-overexpressing metastatic breast cancer : a multicenter phase-II study. Breast Cancer 2006 ; 13 : 166-71.
46. Venturini M, Bighin C, Monfardini S, et al. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2006 ; 95 : 45-53.
47. Chia S, Clemons M, Martin L-A, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer : a multicenter phase II trial. J Clin Oncol 2006 ; 24 : 2773-8.
48. Xu L, Song S, Zhu J, Luo, et al. A phase II trial of trastuzumab + capecitabine as first-line treatment in patients with HER2-positive metastatic breast cancer. J Clin Oncol 2006 ; 24 : 18S ; (Abstract 10615).
49. Tusquets I, Ramos M, Gil M, et al. Preliminary results of docetaxel and trastuzumab combination administered every 21 days in metastatic breast cancer and HER-2 over-expression patients. J Clin Oncol 2006 ; 24 : 18S ; (abstract 10670).
50. Kaufman B, Mackey J, Clemens M, et al. Trastuzumab plus anastrozole prolongs progression-free survival in post menopausal women with HER-2 positive, hormone-dependent metastatic breast cancer. Ann Oncol 2006 ; 17(Suppl 9) : 69.
51. Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007 ; (sous presse).
52. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer : a pilot study. J Clin Oncol 2003 ; 21 : 46-53.
53. Harris L, Burstein HJ, Gelman R, et al. Preoperarive trastuzumab and vinorelbine is a highly active, well tolerated reimen for HER2 3 +/FISH + stage II/III breast cancer. Proc Am Soc Clin Oncol 2003 ; 22 : 22 ; (abstract 86).
54. Coudert B, Arnould L, Moreau L, et al. Preoperative systemic (neoadjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer : results of a multicenter phase II trial. Ann Oncol 2006 ; 17 : 409-14.
55. Ferrant E, Gelly M, Guy F, et al. Taux de réponse complète histologique (RCH) par docetaxel (taxotere) trastuzumab (Herceptin) néoadjuvant dans les cancers du sein HER2-3 + non métastatiques. Bull Cancer 2006 ; 93 : 602 ; (Abstract 14).
56. Sano M, Tabei T, Suemasu K, et al. [Multicenter phase II trial of thrice-weekly docetaxel and weekly trastuzumab as preoperative chemotherapy in patients with HER 2-overexpressing breast cancer - Japan East Cancer Center Breast Cancer Consortium (JECBC) 02 Trial]. Gan To Kagaku Ryoho 2006 ; 33 : 1411-5.
57. Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006 ; 24 : 1831-8.
58. Couturier J, Vincent-Salomon A, Nicolas A, et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 2000 ; 13 : 1238-43.
59. Coudert B, Largillier R, Chollet P, et al. Pathological complete response with neoadjuvant docetaxel, carboplatin and trastuzumab in HER2-positive, locally advanced breast cancer on behalf of the GETN (A) group. Breast Cancer Res Treat 2005 ; 94(Suppl) : 223 (abst. 5050).
60. Wenzel C, Hussian D, Bartsch R, et al. Preoperative therapy with epidoxorubicin and docetaxel plus trasruzumab in patients with primary breast cancer : a pilot study. J Cancer Res Clin Oncol 2004 ; 130 : 400-4.
61. Van Pelt AE, Mohsin S, Elledge RM, et al. Neoadjuvant trastuzumab and docetaxel in breast cancer : preliminary results. Clin Breast Cancer 2003 ; 4 : 348-53.
62. Lybaert W, Wildiers H, Neven P, et al. Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) ± trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC) : preliminary safety and efficacy data. Breast Cancer Res Treat 2006 ; 100(Suppl) : 147-8.
63. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy : results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005 ; 23 : 3676-85.
64. Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase iia amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil : Danish breast cancer cooperative group. J Clin Oncol 2005 ; 23 : 7483-90.
65. Tanner M, Isola J, Wiklund T, et al. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer : Scandinavian Breast Group Trial 9401. J Clin Oncol 2006 ; 24 : 2428-36.
66. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002 ; 8 : 1061-7.
67. Slamon DJ, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients : BCIRG 006 study. Breast Cancer Res Treat 2005 ; 94(Suppl) : 5 (abst. 1).
68. nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in Her2neu positive early breast cancer patients. Breast Cancer Res Treat 2006 ; 100(Suppl).
69. Buzdar A, Valero V, Ibrahim N, et al. Prospective data of additional patients treated with neoadjuvant therapy with paclitaxel followed by FEC chemotherapy with trastuzumab in HER-2 positive operable breast cancer, and an update of initial study population. Breast Cancer Res Treat 2005 ; 94(suppl) : 293 (abstract 5049).
70. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005 ; 353 : 1659-72.
71. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for Operable HER2-positive breast cancer. N Engl J Med 2005 ; 353 : 1673-84.
72. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Trastuzumab in combination with docetaxel or vinorelbine as adjuvat treatment of breast cancer : the FinHer trial. N Engl J Med 2006 ; 354 : 809-20.
73. Mendelsohn J. Targeted cancer therapy. Trans Am Clin Climatol Assoc 2000 ; 111 : 95-111.
74. Etassami A, Bourhis J. Cetuximab : Anti EGF-R monoclonal antibody. Drug Fut 2000 ; 25 : 895-9.
75. Wu X, Rubin M, Fan Z, et al. Involvement of p27 KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996 ; 12 : 1397-403.
76. Peng D, Fan Z, Lu Y, et al. Anti-epidermal growth factor receptor monoclonal antibody C225 upregulates p27Kip1 and induces G1 arrest in prostatic cancer cell line DU 145. Cancer Res 1996 ; 56 : 3666-9.
77. Ciardiello F, Damiano V, Bianco R, et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 1996 ; 88 : 1770-6.
78. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing in nude mice. Clin Cancer Res 1999 ; 5 : 257-65.
79. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C-225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000 ; 6 : 3739-47.
80. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in human tumor xenograft model. Clin Cancer Res 1995 ; 1 : 1311-8.
81. Pewett M, Rockwell P, Rockwell RF, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Tumor Immunol 1996 ; 19 : 419-27.
82. Overholser JP, Prewett MC, Hooper AT, et al. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000 ; 89 : 74-82.
83. Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994 ; 269 : 27595-602.
84. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone-C225 in nice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000 ; 6 : 4874-84.
85. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gencitabine results in regression of human pancreatic carcinoma growing orthopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000 ; 6 : 1936-48.
86. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radio-response by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000 ; 6 : 701-6.
87. Woodburn JR, Barker AJ. 4-anilinoquiinazolines-a potential new therapy for major human solid tumors overexpressing the EGF receptor. Br J Cancer 1997 ; 74 : 213-568.
88. Nicholson RI, Gee JMW, Barrow D, et al. Endocrine resistance in breast cancer can involve a switch towards EGFR signalling pathways and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD1839. Proc AACR-NCI-EORTC Meeting 1999 ; 7.
89. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin Cancer Res 2000 ; 6 : 2053-63.
90. Chan KC, Knox F, Woodburn JR, et al. Blockage of growth factor receptors in ductal carcinoma in situ of the breast inhibits epithelial proliferation. Br J Surg 2001 ; 88 : 412-8.
91. Lawrence DS, Niu J. Protein kinase inhibitors : the tyrosine specific protein kinases. Pharmacol Ther 1998 ; 77 : 81-114.
92. Cullinane C, Kleinschmidt M, Webster LK. Antitumor activity of ZD 1839 (Iressa) in combination with cisplatin in NIH3T3 cells expressing human epidermal growth factor receptor. Proc Am Assoc Cancer Res 2000 ; 41 : 482 ; (abstract 3073).
93. Sirotnak FM, Zakowsky MF, Miller VA, et al. Efficacy of cytotoxic agents againts human tumor xenografts is markedly enhanced by coadministration of ZD 1839 (Iressa) an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000 ; 6 : 4885-92.
94. Budillon A, Di Gennaro E, Barbarino M, et al. ZD 1839, an epidermal growth factor receptor tyrosine kinase inhibitor, upregulates p27kip1 inducing G1 arrest and enhancing the antitumoreffect of interferon α. Proc Am Assoc Cancer Res 2000 ; 41 : 773 ; (abstract 4910).
95. Ohmori T, Ao Y, Nishio K, et al. Low dose cisplatin can modulate the sensitivity of human non-small cell lung carcinoma cells to EGFR tyrosine kinase inhibitor (ZD 1939, Iressa) in vivo. Proc Am Assoc Cancer Res 2000 ; 41 : 482 ; (abstract 3072).
96. Raben D, Helfrich B, Phistry M et al. ZD 1839 (Iressa) an EGFR-TK1, potentiates radiation/chemotherapy cytotoxicity in human non-small cell lung (NSCLC) cell lines. 11 th NCI-EORTC-AACR symposium on New drugs in cancer therapy. Abs LB4, Amsterdam, November 7-10, 2000.
97. William K, Telfer B, Stratford IJ, et al. An evaluation of the EGFR tyrosine kinase inhibitor ZD1839 (Iressa) in combination with ionising radiation. Amsterdam : AACR symposium on New drugs in cancer therapy. Abs LB3, 2000 ; (November 7-10).
98. Normanno N, Campiglio M, De Luca A, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab on human breast cancer cell growth. Proc Am Assoc Cancer Res 2000 ; 42 : 774 ; (abstract 4156).
99. Anido J, Albanell J, Rojo F, et al. Inhibition by ZD 1839 (Iressa) of epidermal growth factor (EGF) and heregulin induced signaling pathways in human breast cancer cells. Proc Am Soc Clin Oncol 2001 ; 21 : 429 ; (abstract 1712).
100. Ciardiello F, Troiani T, Caputo F, et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006 ; 94 : 1604-9.
101. Moulder SL, Yakes FM, Bianco R, et al. A rationale for the use of small molecule EGF receptor tyrosine kinase inhibitor against HER2/neu (erbB-2) overexpressing breast tumors cells. Proc Am Assoc Cancer Res 2000 ; 42 : 774 ; (abstract 4573).
102. Ciardiello F, Tortora G. A novel approch in the treatment of cancer : targeting the epidermal growth factor receptor. Clin Cancer Res 2001 ; 7 : 2958-70.
103. Rodon J, Beeram M, Debono JS, et al. Impressive anti-tumor activity of combined erbB1 and erbB2 blockade with OSI-774 (erlotinib) and trastuzumab in combination with weekly paclitaxel in patients with trastuzumab refractory breast cancer in a phase I pharmacokinetics study. Breast Cancer Res Treat 2006 ; 100(Suppl) : 68-9 (abst. 1092).
104. Geyer CE, Forster JK, Cameron D, et al. A phase III randomized, open-label, international study comparing lapatinib and cepecitabine vs. capecitabine in women with refractory advanced or metastatic breast cancer (EGF100151). J Clin Oncol 2006 : 18S ; (abstract).
105. Cameron D, Stein S, Zaks T, et al. Lapatinib plus capecitabine shows superior efficacy compared to capecitabine alone in patients with ErbB2 positive advanced or metastatic breast cancer - initial biomarker data. Breast Cancer Res Treat 2006 ; 100(Suppl) : 5 (abst. 2).
106. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with HER2 + breast cancer. J Clin Oncol 2006 ; 24 : 18S ; (abstract 503).
107. Gomez HL, Chavez D, Doval DC, et al. Results from a phase II randomized study of lapatinib as first line-treatment for patients with HER-2-amified locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006 ; 100(Suppl) : 68 (abstr. 1090).
108. Iwata H, Toi M, Fujiwara Y, et al. Phase II clinical study of lapatinib (Tykerb) in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat 2006 ; 100(Suppl) : 11 ; (abstract 1091).
109. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002 ; 20 : 719-26.
110. Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005 ; 23 : 2162-71.
111. Cristofanilli M, Boussen H, Baselga J, et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res Treat 2006 ; 5(Suppl) : 5 (abstr. 1).
112. Dai Q, Ling YH, Lia M, Zou YY, Kroog G, Iwata KK, et al. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlorinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res 2005 ; 11 : 1572-8.
113. Koch KM, Paul E, Beelen AP, Pandite L. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. Breast Cancer Res Treat 2004 ; 88(Suppl) : 220 (abstr. 3043).
114. Storniolo AM, Burris HA, Overmoyer B, et al. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. Breast Cancer Res Treat 2005 ; 94(Suppl) : 64 (absrr. 1073).
115. Bacus SS, Trusk P, Lyass L, et al. Inhibition of ErbB1/2 by small molecule tyrosine kinase inhibitors, but not trastuzumab, affects metabolic pathways : implication to cardiac toxicity. Breast Cancer Res Treat 2006 ; 100(Suppl) : 29-30 (abstr. 304).
116. Slichenmyer WJ, Fry DW. Anticancer rherapy targeting the ErbB family receptor tyrosine kinases. Semin Oncol 2001 ; 28 : 67-79.
117. Allen LF, Lenehan PF, Eiseman IA, et al. Potential benefits of the reversible Pan-erbB Inhibitor, CI-1033, in the Treatment of breast cancer. Semin Oncol 2002 ; 29 : 11-21.
118. Slichenmyer W, Elliott WL, Fry DW. CI-1033, a Pan-erbB tyrosine kinase inhibitor. Semin Oncol 2001 ; 28(Suppl) : 80-5.
119. Campone M, Kerbrat P, Roche H, Bennouna J, Cuilliere JC, Le Mevel B, et al. Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction : applications in breast cancer. Bull Cancer 2003 ; 90 : 851-6.
120. Hussain S, Sun Y, Kha V, Sun AW. Effects of combination treatment with proteasome inhibitor, mTOR inhibitor and Notch inhibitor on estrogen receptor negative human breast cancer cell line MDA-MB-231. Breast Cancer Res Treat 2006 ; 100(Suppl) : 71-2 (abstr. 1101).
121. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, et al. Estrogen recepror pathways to AP-1. J Steroid Biochem Mol Biol 2000 ; 74 : 311-7.
122. Razandi M, Pedram A, Park ST, Levin ER. Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 2003 ; 278 : 2701-12.
123. Levin ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 2003 ; 17 : 309-17.
124. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000 ; 407 : 538-41.
125. Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000 ; 20 : 5041-7.